Zymeworks Up 10% On Positive Study Results Of Zanidatamab In Biliary Tract Cancer Treatment

On:

Shares of Zymeworks Inc. (ZYME) are rising more than 10% Monday morning after reporting positive topline results from the Phase 2b study of zanidatamab in patients with biliary tract cancers.

Topline results from the Phase 2b HERIZON-BTC-01 study showed that 41.3% of enrolled patients with HER2-amplified and expressing disease achieved an objective response after treatment with zanidatamab.

Full results from the study are expected to be presented in 2023.

ZYME is at $7.17 currently. It has traded in the range of $4.11-$17.27 in the last 1 year.

Source: Read Full Article

Lates News:
  1. US Presidential Candidate Pledges Dollar Backing With Bitcoin, No Bitcoin Capital Gains Tax
  2. SolarEdge Tanks After Decreasing Q3 Outlook
  3. Cryptos Muted As Geopolitics And Interest Rate Worries Bother
  4. Bitcoin Predicted To Soar Past $35,000 By Summer As Wallets Holding At Least 1 BTC Hits The 1 Million Mark
  5. This Bitcoiner Just Paid a Whopping $500,000 In Transaction Fees for A 0.074 BTC Transfer